Bulk Pharmaceutical API Sources for daunorubicin hydrochloride

Bulk Pharmaceutical API Sources for daunorubicin hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		W4013_SIGMA
Sigma-Aldrich		D8809_SIAL
Sigma-Aldrich		30450_SIGMA
Molport		MolPort-002-498-910
Amadis Chemical		A816764
TimTec		ST51042193
AKos Consulting & Solutions		AKOS015920259

Bulk Active Pharmaceutical Ingredient (API) Sources for: Daunorubicin Hydrochloride

Last updated: July 31, 2025

---

Introduction

Daunorubicin hydrochloride, a chemotherapeutic agent classified as an anthracycline antibiotic, is predominantly utilized in the treatment of acute myeloid leukemia and other hematological malignancies. As a critical component of various chemotherapy regimens, the quality, purity, and source of daunorubicin hydrochloride API (active pharmaceutical ingredient) directly influence therapeutic efficacy and safety. The global pharmaceutical supply chain for daunorubicin hydrochloride API is diverse and involves multiple manufacturers, each adhering to stringent regulatory standards. This article explores prominent sources, manufacturing considerations, and procurement strategies for bulk daunorubicin hydrochloride API.

---

Global API Manufacturing Landscape for Daunorubicin Hydrochloride

Major API Producers

The primary regions producing daunorubicin hydrochloride API include India, China, European Union countries, and the United States. Each region hosts several manufacturers with capabilities spanning from research-grade to pharmaceutical-grade bulk supplies.

1. India

   India stands as a significant hub for generic API manufacturing due to its robust pharmaceutical industry and cost-effective production. Notable producers include:

   • Sun Pharmaceutical Industries Ltd.
   • Aurobindo Pharma Ltd.
   • Cipla Limited
   • Laurus Labs

   These companies supply daunorubicin hydrochloride API conforming to international standards such as WHO GMP, US FDA, and EMA certifications. Their APIs undergo rigorous quality control, ensuring batch-to-batch consistency and compliance with pharmacopeial requirements.

2. China

   Chinese manufacturers have expanded their presence in the oncology API sector, driven by rapid economic growth and genetic manufacturing capabilities.

   • Hisun Pharmaceutical Co., Ltd.
   • Shenzhen Topfond Pharmaceutical Co., Ltd.
   • Hunan Dongting Pharmaceutical Co., Ltd.

   Chinese APIs often attract global buyers due to competitive pricing, though due diligence regarding regulatory compliance and manufacturing audits is critical.

3. European Union

   Few prominent European manufacturers produce daunorubicin hydrochloride API, primarily catering to local and regional markets with high regulatory standards.

   • Fresenius Kabi (Germany)
   • Sanofi (France)

   These companies prioritize stringent quality assurance protocols, ensuring API integrity suitable for sterile, injectable formulations.

4. United States

   U.S.-based API manufacturers typically supply to national markets or as bulk exports for overseas formulations.

   • BASF Corporation (US subsidiary)
   • Pfizer Inc.

   Their production processes adhere to cGMP standards, with extensive regulatory oversight.

---

Manufacturing Considerations and Quality Requirements

Producing daunorubicin hydrochloride API involves complex synthetic pathways, notably:

• Isolation and purification of daunorubicin from Streptomyces peucetius, a natural bacterial source.
• Chemical modifications to yield hydrochloride salt form.
• Stringent quality control including impurity profiling, residual solvents analysis, microbial limits, and endotoxin testing.

Manufacturers must comply with global pharmacopeial standards (e.g., USP, EP, JP) and regulatory agencies' requirements such as the FDA, EMA, and WHO. Batch consistency, conforming to impurity limits, and stability profiles are critical quality attributes.

---

Procurement and Sourcing Strategies

• Regulatory Due Diligence: Verify manufacturing compliance (GMP, cGMP), and obtain certifications (e.g., FDA 510(k), EMA certificates).
• Supplier Qualification: Engage with reputable, audited vendors with established track records.
• Quality Agreements: Establish clear specifications, quality standards, and testing responsibilities.
• Supply Chain Security: Diversify sources across regions to mitigate geopolitical or supply disruptions.
• Pricing and Lead Time: Evaluate cost-effectiveness balanced with quality adherence considering the urgency of oncology API needs.

---

Emerging Trends and Challenges

• Generic API Market Expansion: Increasing approvals of generic formulations incentivize new API manufacturers to enter the market, possibly affecting pricing dynamics.
• Supply Chain Disruptions: COVID-19 exposed vulnerabilities in global API supply chains, prompting pharma companies to reassess sourcing strategies.
• Regulatory Divergences: Variances in standards across regions necessitate careful supplier validation, especially for APIs exported internationally.
• Environmental and Sustainability Practices: Growing emphasis on greener manufacturing processes influences sourcing decisions.

---

Summary of Key API Suppliers

Region	Notable Manufacturers	Certification Standards
India	Sun Pharma, Aurobindo, Cipla, Laurus Labs	WHO GMP, cGMP, US FDA, EMA
China	Hisun Pharma, Topfond Pharma, Dongting Pharma	CFDA, GMP, ISO
Europe	Fresenius Kabi, Sanofi	EMA, EDQM
United States	BASF, Pfizer	FDA, cGMP

---

Key Takeaways

• The leading global sources of daunorubicin hydrochloride API are India and China, with regional suppliers in Europe and the US providing high-standard, regulated APIs.
• The synthesis of daunorubicin hydrochloride requires strict quality control, with an emphasis on purity, impurity profiling, and compliance with pharmacopeial standards.
• Diversification of suppliers and thorough due diligence are critical strategies to ensure a stable, compliant, and cost-effective supply chain amid global disruptions.
• The evolving pharmaceutical landscape favors suppliers with robust regulatory compliance, environmentally sustainable practices, and proven manufacturing excellence.

---

FAQs

Q1. What are the main suppliers of daunorubicin hydrochloride API globally?
A1. Major suppliers include Indian companies such as Sun Pharma and Aurobindo, Chinese manufacturers like Hisun Pharma, and regional suppliers in Europe and the US like Fresenius Kabi and Pfizer.

Q2. How does regulatory compliance influence API sourcing for daunorubicin hydrochloride?
A2. Regulatory compliance ensures API quality, safety, and efficacy. Certified GMP manufacturing, proper documentation, and adherence to pharmacopeial standards are mandatory to meet international licensing requirements.

Q3. What factors should influence procurement decisions for daunorubicin hydrochloride API?
A3. Quality assurance, regulatory compliance, supplier reputation, pricing, lead times, and supply chain stability are critical factors.

Q4. Are there significant quality differences between APIs from different regions?
A4. Yes, APIs from regions with stringent regulatory oversight (e.g., the EU and US) are generally perceived to have higher compliance and consistency; however, many Indian and Chinese manufacturers also meet or exceed international standards when properly qualified.

Q5. What are emerging challenges in sourcing daunorubicin hydrochloride API?
A5. Challenges include geopolitical tensions, supply chain disruptions, regulatory divergence, and environmental sustainability concerns, all impacting availability and cost.

---

References

1. U.S. Pharmacopeia (USP), "Diclorobenzene)," USP Monographs.
2. WHO International Pharmacopoeia, "Daunorubicin hydrochloride," WHO Specifications.
3. Indian Pharmacopoeia Commission, "Monographs for Oncology APIs," 2022.
4. Chinese Pharmacopoeia Commission, "Oncology Drugs Specifications," 2020.
5. Market intelligence reports for pharmaceutical APIs (e.g., IQVIA, Evaluate Pharma).